- Home
- CDNA vs CDTX Comparison
CDNA vs CDTX Comparison
Compare CDNA & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- CDTX
- Stock Information
- Founded
- CDNA 1998
- CDTX 2012
- Country
- CDNA United States
- CDTX United States
- Employees
- CDNA N/A
- CDTX N/A
- Industry
- CDNA Medical Specialities
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDNA Health Care
- CDTX Health Care
- Exchange
- CDNA Nasdaq
- CDTX Nasdaq
- Market Cap
- CDNA 1.0B
- CDTX 980.1M
- IPO Year
- CDNA 2014
- CDTX 2015
- Fundamental
- Price
- CDNA $12.92
- CDTX $62.08
- Analyst Decision
- CDNA Buy
- CDTX Strong Buy
- Analyst Count
- CDNA 6
- CDTX 11
- Target Price
- CDNA $29.33
- CDTX $52.11
- AVG Volume (30 Days)
- CDNA 2.1M
- CDTX 1.3M
- Earning Date
- CDNA 07-30-2025
- CDTX 08-12-2025
- Dividend Yield
- CDNA N/A
- CDTX N/A
- EPS Growth
- CDNA N/A
- CDTX N/A
- EPS
- CDNA 1.07
- CDTX N/A
- Revenue
- CDNA $346,421,000.00
- CDTX $302,000.00
- Revenue This Year
- CDNA $13.31
- CDTX N/A
- Revenue Next Year
- CDNA $15.46
- CDTX N/A
- P/E Ratio
- CDNA $12.11
- CDTX N/A
- Revenue Growth
- CDNA 25.92
- CDTX N/A
- 52 Week Low
- CDNA $10.96
- CDTX $10.14
- 52 Week High
- CDNA $34.84
- CDTX $61.60
- Technical
- Relative Strength Index (RSI)
- CDNA 28.64
- CDTX 71.62
- Support Level
- CDNA $11.62
- CDTX $50.25
- Resistance Level
- CDNA $13.15
- CDTX $61.60
- Average True Range (ATR)
- CDNA 1.36
- CDTX 4.09
- MACD
- CDNA -0.91
- CDTX 0.01
- Stochastic Oscillator
- CDNA 18.04
- CDTX 78.88
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.